NCT01181375Active, not recruiting
Predictive Assays In Cervix Cancer
Predictive Assays in Cervix Cancer: Assessment of Hypoxia, Interstitial Fluid Pressure, and Tissue and Plasma Biomarkers of Hypoxia (CXTF10)
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
The experiments outlined in this proposal will compare a number of currently available techniques for assessing hypoxia and interstitial fluid pressures in patients with cervix cancer. The aim of these experiments is to establish the relationship of the clinically relevant outcome measures of tumour control and survival following radiation therapy with these biological characteristics of carcinoma of the cervix relevant to tumour hypoxia. These characteristics will be assessed in patients undergoing treatment using techniques which have reached an appropriate level of development for clinical evaluation and aim to determine the best technique for determining these parameters of the tumour microenvironment. A number of novel strategies directed at the microenvironment are undergoing or soon will be undergoing clinical evaluation and selection of appropriate patients for these trials is of great importance.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 12 Aug 2010
- Start date
- 1 Aug 2006
- Primary completion date
- Aug 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Cervical cancer
- NCT number
- NCT01181375
What you commit to
- Study type: Interventional
- Planned participants: 500
- From 1 Aug 2006 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Histologic diagnosis of cervix cancer
- A decision to treat using radiation therapy according to the existing treatment policies of the PMH Gynecology Group
- Clinical stage IB-IV with grossly evident cervical disease
- No distant metastases
- No cytotoxic anti-cancer therapy for cervical carcinoma prior to study entry
- Signed informed consent
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Health Network, Princess Margaret Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.